< All Topics

Regulatory Pharmacovigilance in EU

In the European Union (EU), regulatory pharmacovigilance is the system of activities and measures designed to ensure the safety and efficacy of medicinal products for human use. The European Medicines Agency (EMA) is the central regulatory authority responsible for the regulation and pharmacovigilance of medicinal products in the EU.

The key components of regulatory pharmacovigilance in the EU include:

  1. Risk management: The EMA uses a risk management approach to ensure that the benefits of a medicinal product outweigh its risks. This includes the assessment of risks and the implementation of risk minimization measures.
  2. Signal detection: The EMA monitors safety data to identify any potential safety concerns that may arise with a medicinal product.
  3. Adverse event reporting: The EMA has established the EudraVigilance system, a centralized electronic database for the collection and analysis of suspected adverse drug reactions (ADRs) in the EU. Marketing authorization holders are required to report ADRs to the EMA through this system.
  4. Post-authorization safety studies: The EMA may require post-authorization safety studies to be conducted to further investigate the safety profile of a medicinal product after it has been authorized for marketing.
  5. Referral procedures: The EMA may initiate referral procedures for a medicinal product if there is a concern regarding its safety, efficacy, or quality.
  6. Communication and transparency: The EMA communicates safety information to healthcare professionals, patients, and the general public through a variety of channels, including its website and public assessment reports.
  7. Good pharmacovigilance practices: The EMA has established a set of guidelines for good pharmacovigilance practices (GVP) to ensure that pharmaceutical companies follow consistent and high-quality standards for pharmacovigilance activities.

Overall, the regulatory pharmacovigilance system in the EU is designed to ensure that medicinal products are safe and effective for patients. The EMA works with national regulatory authorities in EU member states to ensure that pharmacovigilance activities are consistent and effective across the region.

You may be interested in the programs below: